Kun Ma1, Jiayun Liu2, Youjin Wang1, Yubin Zhong3, Zhenfeng Wu2, Ruiying Fan4, Shanfeng Guo1. 1. Department of Interventional Radiology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. 2. Department of Surgical Oncology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. 3. Department of General Surgery, Yixing People's Hospital, Yixing, China. 4. Department of Medical Oncology, Taikang Xianlin Drum Tower Hospital, Nanjing, China.
Abstract
BACKGROUND: Our study aims to investigate changes in cell-free DNA (cfDNA) concentration and integrity in primary hepatocellular carcinoma (PHC) patients before and after transcatheter arterial chemoembolization (TACE) treatment and their influence on the evaluation of prognosis of the disease. METHODS: A total of 84 PHC patients admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine from December 2016 to December 2017 were included as the study group, while 55 healthy people served as the control group. Plasma cfDNA concentration and integrity were determined using qRT-PCR. The correlation between cfDNA concentration/integrity and clinical characteristics of PHC patients were analyzed. A ROC curve was used to investigate the sensitivity and specificity of cfDNA as detection indices. Univariate and multivariate analyses were used to analyze factors affecting recurrence in PHC patients and compare recurrence-free survival (RFS) of PHC patients with high cfDNA expression and low cfDNA expression. RESULTS: Plasma cfDNA concentration and integrity were significantly higher in PHC patients before TACE treatment than in healthy people and significantly lower after treatment than before (P<0.05). The cfDNA concentration was significantly correlated with tumor size, lymph node metastasis, TNM stage, and BCLC stage, while cfDNA integrity was significantly correlated with tumor size, TNM stage, and BCLC stage (P<0.05). ROC results showed that the area under the curve (AUC) value of cfDNA concentration was the largest, with an optimal cut-off of 10.51 ng/mL. Multivariate regression analysis for COX showed that the TNM stage, cfDNA concentration, and AFP were independent risk factors that affected PHC patients' survival. CONCLUSIONS: Plasma cfDNA concentration in PHC patients is more sensitive and specific than any other tumor marker. It is an independent risk factor for PHC patients treated with TACE. Therefore, it is hypothesized cfDNA is a potential biomarker for prognostic evaluation of PHC patients treated with TACE. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Our study aims to investigate changes in cell-free DNA (cfDNA) concentration and integrity in primary hepatocellular carcinoma (PHC) patients before and after transcatheter arterial chemoembolization (TACE) treatment and their influence on the evaluation of prognosis of the disease. METHODS: A total of 84 PHC patients admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine from December 2016 to December 2017 were included as the study group, while 55 healthy people served as the control group. Plasma cfDNA concentration and integrity were determined using qRT-PCR. The correlation between cfDNA concentration/integrity and clinical characteristics of PHC patients were analyzed. A ROC curve was used to investigate the sensitivity and specificity of cfDNA as detection indices. Univariate and multivariate analyses were used to analyze factors affecting recurrence in PHC patients and compare recurrence-free survival (RFS) of PHC patients with high cfDNA expression and low cfDNA expression. RESULTS: Plasma cfDNA concentration and integrity were significantly higher in PHC patients before TACE treatment than in healthy people and significantly lower after treatment than before (P<0.05). The cfDNA concentration was significantly correlated with tumor size, lymph node metastasis, TNM stage, and BCLC stage, while cfDNA integrity was significantly correlated with tumor size, TNM stage, and BCLC stage (P<0.05). ROC results showed that the area under the curve (AUC) value of cfDNA concentration was the largest, with an optimal cut-off of 10.51 ng/mL. Multivariate regression analysis for COX showed that the TNM stage, cfDNA concentration, and AFP were independent risk factors that affected PHC patients' survival. CONCLUSIONS: Plasma cfDNA concentration in PHC patients is more sensitive and specific than any other tumor marker. It is an independent risk factor for PHC patients treated with TACE. Therefore, it is hypothesized cfDNA is a potential biomarker for prognostic evaluation of PHC patients treated with TACE. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Benjamin Arko-Boham; Nii Ayite Aryee; Richard Michael Blay; Ewurama Dedea Ampadu Owusu; Emmanuel Ayitey Tagoe; Eshirow-Sam Doris Shackie; Ama Boatemaa Debrah; Nii Armah Adu-Aryee Journal: Cancer Genet Date: 2019-04-23
Authors: Muhammad Ibrahim Alhadi Edoo; Vikram Kumar Chutturghoon; Gyabaah Kwabena Wusu-Ansah; Hai Zhu; Tao Yang Zhen; Hai Yang Xie; Shu-Sen Zheng Journal: Iran J Public Health Date: 2019-02 Impact factor: 1.429
Authors: Dimitrios Moris; Ioannis D Kostakis; Nikolaos Machairas; Anastasia Prodromidou; Diamantis I Tsilimigras; Kadiyala V Ravindra; Debra L Sudan; Stuart J Knechtle; Andrew S Barbas Journal: PLoS One Date: 2019-07-31 Impact factor: 3.240